ADVENZYMESNSEAdvanced Enzyme Technologies LimitedHighNeutral
Announced Sat, 9 May, 2026 · 14:17 IST

Advanced Enzyme Technologies Limited has informed the Exchange regarding Change in Auditors of the company.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionNegative Operating CashflowResults View source PDFExplain this filing

ADVENZYMES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.8%1-day move
₹361.75
prior close
₹378.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+7.4+6.0+6.9+6.6+2.8+1.2+0.8+0.1-0.1+7.7+7.5+0.2-8.7-17.5
Up moveDown movePending
AI summary

Advanced Enzyme Technologies reported FY26 consolidated revenue of Rs 7,457.57 million, up 17% from Rs 6,369.10 million in FY25. Profit after tax grew 29.6% to Rs 1,736.08 million from Rs 1,339.74 million, with EPS at Rs 15.08 versus Rs 11.72. The Board recommended a final dividend of Rs 1.35 per share (67.5% on face value Rs 2) but deferred any interim dividend, stating they want to preserve capital for potential strategic actions. MSKA & Associates LLP was reappointed as statutory auditors for a second 5-year term. The auditor issued an unmodified (clean) opinion on the financial statements.

Likely market impact

Strong financial performance with nearly 30% PAT growth demonstrates operational efficiency. The deferred interim dividend despite healthy cash flows signals potential strategic plans ahead. Clean audit opinion with no qualifications is positive for investor confidence.